2017
Primary healthcare-based integrated care with opioid agonist treatment: First experience from Ukraine
Morozova O, Dvoriak S, Pykalo I, Altice FL. Primary healthcare-based integrated care with opioid agonist treatment: First experience from Ukraine. Drug And Alcohol Dependence 2017, 173: 132-138. PMID: 28242537, PMCID: PMC5545131, DOI: 10.1016/j.drugalcdep.2016.12.025.Peer-Reviewed Original ResearchMeSH KeywordsAdultBuprenorphineCross-Sectional StudiesDelivery of Health Care, IntegratedFemaleHealth Services ResearchHIV InfectionsHumansMaleMethadoneMiddle AgedOpiate Substitution TreatmentOpioid-Related DisordersPatient DropoutsPatient SatisfactionPilot ProjectsPrimary Health CareQuality of LifeSubstance Abuse, IntravenousUkraineConceptsOpioid agonist therapyPrimary healthcare clinicsIntegrated carePHC staffHIV patientsHIV epidemicOAT patientsOpioid agonist treatmentStandard of careAddiction treatment settingsAgonist therapyObservational cohortMiddle-income countriesAgonist treatmentPrimary careComprehensive healthcare servicesPWIDHealthcare clinicsAddiction clinicPatientsTreatment settingsDrug usersPilot studyCareHealthcare services
2013
Tuberculosis screening in a novel substance abuse treatment center in Malaysia: Implications for a comprehensive approach for integrated care
Al-Darraji HA, Wong KC, Yeow DG, Fu JJ, Loeliger K, Paiji C, Kamarulzaman A, Altice FL. Tuberculosis screening in a novel substance abuse treatment center in Malaysia: Implications for a comprehensive approach for integrated care. Journal Of Substance Use And Addiction Treatment 2013, 46: 144-149. PMID: 24074846, PMCID: PMC5189907, DOI: 10.1016/j.jsat.2013.08.023.Peer-Reviewed Original ResearchConceptsLatent TB infectionTuberculin skin testingDrug treatment centersSubstance abuse treatment centersTreatment centersKey high‐risk groupsVoluntary drug treatment centresCross-sectional convenience surveyHigh-risk groupComplex treatment needsArrest/incarcerationActive diseaseTB infectionTB screeningTST positivitySkin testingRisk groupsTreatment needsHeroin useStandardized questionnaireTreatment entryIntegrated careTreatment programTuberculosisPrevalence
2011
The Cost of Integrated HIV Care and Buprenorphine/Naloxone Treatment: Results of a Cross-Site Evaluation
Schackman BR, Leff JA, Botsko M, Fiellin DA, Altice FL, Korthuis PT, Sohler N, Weiss L, Egan JE, Netherland J, Gass J, Finkelstein R. The Cost of Integrated HIV Care and Buprenorphine/Naloxone Treatment: Results of a Cross-Site Evaluation. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2011, 56: s76-s82. PMID: 21317599, PMCID: PMC3270565, DOI: 10.1097/qai.0b013e31820a9a66.Peer-Reviewed Original ResearchConceptsBuprenorphine/naloxone treatmentIntegrated care patientsBuprenorphine/naloxoneNaloxone treatmentCare patientsClinic costsIntegrated careCross-site evaluationHIV clinical sitesIntegrated HIV careUrine toxicology analysisMedian monthly costPotential cost offsetsToxicology analysisHIV careIntegrated HIVSimilar patientsPhysician encountersPatient costsClinic settingMedian numberProvider encountersPatient timePatientsClinical sites